![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 21, 2017 10:49:11 PM
Dror Harats
So thank you very much Sara, and actually that's a very good question. The DSMC, whenever they meet I guess the full non-blinded data for safety and of course part of the safety is a number of additional mortality, which of course look for safety reasons. But because our primary endpoint is overall survival and the number of deaths actually, so they look at efficacy on each time. So far they looked at it twice and gave us a green light to go forward; actually in April, and that's why we came with a press release at that point, because it's not just safety, they’re actually looking at the primary endpoint of this each time that they are looking at the data.
They felt that we don't even need the phone call and we suggest now that everything looks great and we should go forward. And later on when we discuss DSMC meeting that we are -- that they are going to have in the third quarter, in September, actually we had called to discuss this and they told us that everything looks quite right, and we should go forward. What they’re going to do in the meeting, in September, they're going to get data which is going to be cut -- the cutting date going to be sometimes in August. But of course, you have to make sure that the data is relatively clean.
And then they look at the data where they get listing and tables that include all the safety issues, but there also includes the survival of the two different -- includes the number of tests of the two different cohorts. The cohorts that’s getting VB-111 with of Avastin and the cohort to control arm that getting just Avastin. So of course, it’s not a formal efficacy look but whenever they look, they look at efficacy. The only difference between formal survival analysis, which actually or utility analysis, which was planned for this time, but unfortunately or fortunately, because we recruited patients ahead of time, it will actually almost clash with the end of the trial is that when you do a formal futility analysis you have to clean the data the same way that you do when you look at the data at the end of the trial. And that usually take about 60 to sometimes 90 days and that’s going to clash actually with the end of the trial and closing the data. And therefore, in the discussion with the FDA, it was clear that the way to do it is the regular look that the DSMC going to look. But they will have all the information. And of course, you’re saying we’ll see any alarming safety or mortality data, we will know about it right away.
Recent VBLT News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/29/2024 08:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:34:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:31:04 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:40:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:36 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/01/2024 09:19:40 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/20/2024 09:01:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:30:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:15:22 PM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM